<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03480672</url>
  </required_header>
  <id_info>
    <org_study_id>ADRISK</org_study_id>
    <nct_id>NCT03480672</nct_id>
  </id_info>
  <brief_title>Postoperative aRCH With Cisplatin Versus aRCH With Cisplatin and Pembrolizumab in Locally Advanced Head and Neck Squamous Cell Carcinoma</brief_title>
  <official_title>Postoperative Adjuvant Radiochemotherapy (aRCH) With Cisplatin (C) Versus aRCH With C and Pembrolizumab (P) in Locally Advanced Head and Neck Squamous Cell Carcinoma (HNSCC); Multicenter Randomized Phase II Study Within the German Interdisciplinary Study Group of German Cancer Society (IAG KHT); Pembro-Adjuvant-highRisk</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Leipzig</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Leipzig</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This trial evaluates the addition of pembrolizumab to standard postoperative adjuvant
      radiochemotherapy in the treatment of patients with locally advanced intermediate and high
      risk head and neck squamous cell carcinoma (HNSCC).
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 6, 2018</start_date>
  <completion_date type="Anticipated">August 2022</completion_date>
  <primary_completion_date type="Anticipated">August 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event Free Survival (EFS)</measure>
    <time_frame>24 months</time_frame>
    <description>time from randomization to the first event (i.e. locoregional or distant recurrence, initiation of a new anti-cancer treatment death from any cause)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>24 months</time_frame>
    <description>time from randomization to death from any cause</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>HNSCC</condition>
  <arm_group>
    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Application of pembrolizumab, i.v., in 3-week cycle (q3w) 200 mg, in combination with standard treatment (adjuvant radio-chemotherapy aRCH)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>aRCH</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>adjuvant radio-chemotherapy (aRCH)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab 25 MG/1 ML Intravenous Solution [KEYTRUDA]</intervention_name>
    <description>intravenous application, 12 months, in 3-week cycle (q3w) 200 mg</description>
    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>adjuvant radiochemotherapy</intervention_name>
    <description>adjuvant radiochemotherapy with cisplatin</description>
    <arm_group_label>Pembrolizumab + aRCH</arm_group_label>
    <arm_group_label>aRCH</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Macroscopically complete resection of newly diagnosed (not recurrent, not secondary
             primary) advanced squamous-cell carcinoma arising in the oral cavity, oropharynx,
             larynx, or hypopharynx

          2. Advanced stage III, IVA/B HNSCC according to the TNM classification version 7th
             edition (Note! The 8th edition will not be used, please adhere to the national cancer
             institute guidelines)

          3. Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1; performance
             status allows adjuvant chemo radiation with cisplatin.

          4. Had either intermediate or high-risk characteristics, i.e. any or all of the
             following:

               -  histologic evidence of invasion of two or more regional lymph nodes

               -  extracapsular extension of nodal disease,

               -  microscopically involved mucosal margins of resection (R1) or margins of
                  resection &lt; 5mm (R0)

          5. Had pathological histologic assessment of p16 (only oropharyngeal carcinoma)

          6. Be &gt; 18 years of age

          7. Written informed consent

          8. Demonstrate adequate organ function

          9. Female subject of childbearing potential should have a negative pregnancy test within
             3 days prior to receiving the first dose of study medication.

         10. Female subjects of childbearing potential must be willing to use an adequate method of
             contraception, for the course of the study through 120 days after the last dose of
             study medication.

         11. Reproductive male subjects must agree to use an adequate method of contraception,
             starting with the first dose of study therapy through 120 days after the last dose of
             study therapy

        Exclusion Criteria:

          1. Concurrent participation in any other interventional clinical trial or participation
             in any other interventional trial within one month before enrolment into this trial.

          2. Diagnosis of immunodeficiency or is receiving systemic steroid therapy or any other
             form of immunosuppressive therapy within 7 days before enrolment into this trial.

          3. Known history of active TB (Bacillus Tuberculosis)

          4. Hypersensitivity to Pembrolizumab or comparable medicinal products or any of its
             excipients.

          5. Prior anti-cancer monoclonal antibody (mAb) therapy within one month before enrolment
             into this trial or who has not recovered (i.e., ≤ Grade 1 (NCI CTCAE Grade) at
             baseline) from adverse events due to agents administered more than one month earlier.

          6. Prior chemotherapy, targeted small molecule therapy, or radiation therapy within one
             month before enrolment into this trial or who has not recovered (i.e., ≤ grade 1 (NCI
             CTCAE Grade) at baseline) from adverse events due to a previously administered agent.

               1. Note: Subjects with ≤ Grade 2 (NCI CTCAE Grade) neuropathy are an exception to
                  this criterion and may qualify for the study.

               2. Note: If subject received major surgery, they must have recovered adequately from
                  the toxicity and/or complications from the intervention prior to starting
                  therapy.

          7. Known additional malignancy that is progressing or requires active treatment.
             Exceptions include basal cell carcinoma of the skin or squamous cell carcinoma of the
             skin that has undergone potentially curative therapy or in situ cervical cancer.

          8. Active autoimmune disease that has required systemic treatment in the past 2 years
             prior to enrolment (i.e. with use of disease modifying agents, corticosteroids or
             immunosuppressive drugs). Replacement therapy (e g., thyroxine, insulin, or
             physiologic corticosteroid replacement therapy for adrenal or pituitary insufficiency,
             etc.) is not considered a form of systemic treatment.

          9. Evidence of interstitial lung disease or history of (non-infectious) pneumonitis that
             required steroids within the last 6 months before enrolment into this trial, or
             current pneumonitis.

         10. Active infection requiring systemic therapy.

         11. Suspected lack of compliance

         12. Is pregnant or breastfeeding, or expecting to conceive or father children within the
             projected duration of the trial, starting with the baseline visit through 120 days
             after the last dose of trial treatment.

         13. HIV, HBV or HCV infection

         14. Application of a live vaccine within one month of enrolment.

         15. Hypersensitivity to cisplatin or any of its excipients

         16. Any potential relationship to the investigator/his deputy or to medical staff of the
             study team, to the coordinating investigator or is an employee of the study sit
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Dietz, Prof. Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Leipzig</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Dietz, Prof. Dr.</last_name>
    <phone>0049 34197</phone>
    <phone_ext>21700</phone_ext>
    <email>andreas.dietz@medizin.uni-leipzig.de</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anett Schmiedeknecht, Dr.</last_name>
    <phone>0049 34197</phone>
    <phone_ext>16256</phone_ext>
    <email>anett.schmiedeknecht@zks.uni-leipzig.de</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Charité - Universitätsmedizin, CVK und CCM, Klinik für Hals-Nasen-Ohrenheilkunde</name>
      <address>
        <city>Berlin</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Steffen Dommerich, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Bielefeld, Onkologie/Hämatologie/ Palliativmedizin</name>
      <address>
        <city>Bielefeld</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Martin Görner, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Bonn; Med. Klinik III / ZIM, Hämatologie/Onkologie</name>
      <address>
        <city>Bonn</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Brossart, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Düsseldorf, Klinik für Strahlentherapie und Radiologische Onkologie</name>
      <address>
        <city>Düsseldorf</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Balint Tamaskovics, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Helios Klinikum Erfurt GmbH, Klinik für Hals-Nasen-Ohrenheilkunde</name>
      <address>
        <city>Erfurt</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kristin Möller, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Essen, Klinik und Poliklinik für Strahlentherapie</name>
      <address>
        <city>Essen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christoph Gauler, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Jena, Klinik für Hals-Nasen-Ohrenheilkunde</name>
      <address>
        <city>Jena</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Orlando Guntinas-Lichius, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Department of Head Medicine and Oral Health, University of Leipzig</name>
      <address>
        <city>Leipzig</city>
        <zip>04103</zip>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andreas Dietz, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Mannheim, Hals-Nasen-Ohren Klinik</name>
      <address>
        <city>Mannheim</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicole Rotter, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ernst von Bergmann Klinikum Potsdam, Zentrum für Hämatologie, Onkologie und Strahlenheilkunde, Klinik für Hämatologie und</name>
      <address>
        <city>Potsdam</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Georg Maschmeyer, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Regensburg, Klinik und Poliklinik für Strahlentherapie</name>
      <address>
        <city>Regensburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Matthias Hautmann, Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Stuttgart - Katharinenhospital, Klinik für Radioonkologie und Strahlentherapie</name>
      <address>
        <city>Stuttgart</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marc Münter, Prof. Dr.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Universitätsklinikum Würzburg; Klinik und Poliklinik für Strahlentherapie</name>
      <address>
        <city>Würzburg</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Victor Lewitzki, Dr.</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>September 2019</verification_date>
  <study_first_submitted>March 21, 2018</study_first_submitted>
  <study_first_submitted_qc>March 21, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 29, 2018</study_first_posted>
  <last_update_submitted>September 27, 2019</last_update_submitted>
  <last_update_submitted_qc>September 27, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">September 30, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Leipzig</investigator_affiliation>
    <investigator_full_name>Andreas Dietz</investigator_full_name>
    <investigator_title>Prof. Dr. med.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma, Squamous Cell</mesh_term>
    <mesh_term>Squamous Cell Carcinoma of Head and Neck</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

